替格瑞洛单药对比替格瑞洛联合阿司匹林对急性冠脉综合征患者主要出血与心血管事件的影响:TICO随机临床试验
TICO多中心随机试验纳入3056例接受药物洗脱支架的急性冠脉综合征患者,比较3个月双联抗血小板治疗后转为替格瑞洛单药与替格瑞洛为基础12个月双联治疗。
要点
- ACS患者药物洗脱支架术后3个月双联治疗转替格瑞洛单药可降低1年净不良临床事件。
- 替格瑞洛单药主要出血风险低于替格瑞洛为基础12个月双联治疗。
- 主要心脑血管不良事件两组无显著差异,需结合研究人群与低于预期事件率解读。
核心结论
- ACS患者药物洗脱支架术后3个月双联抗血小板治疗转为替格瑞洛单药,相比替格瑞洛为基础12个月双联治疗,1年主要出血与心血管事件复合终点有适度但统计学显著的降低。
研究设计与样本
- 多中心随机临床试验,2015年8月至2018年10月在韩国38个中心纳入3056例接受药物洗脱支架的ACS患者,随访至2019年10月完成。
- 患者随机接受3个月双联治疗后替格瑞洛单药(90 mg每日两次,n=1527)或替格瑞洛为基础12个月双联治疗(n=1529)。
- 2978例(97.4%)完成试验;平均年龄61岁,女性628例(20%),ST段抬高型心肌梗死占36%。
主要发现
- 10个预设次要终点中有8个无显著差异。
关键数值与推荐
- 主要终点定义为1年净不良临床事件,即主要出血与不良心脑血管事件(死亡、心肌梗死、支架血栓、卒中或靶血管血运重建)的复合终点。
- 预设次要终点包括主要出血和主要心脑血管不良事件。
临床怎么用
- 对于接受药物洗脱支架的ACS患者,可考虑在3个月双联抗血小板治疗后转为替格瑞洛单药,以降低出血与净不良临床事件风险。
- 转换决策需结合患者缺血与出血风险个体化评估,并注意本研究人群特征与低于预期的事件率。
局限性
- 研究人群特征可能影响结果外推。
- 事件率低于预期,解读试验结果时应予以考虑。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Discontinuing aspirin after short-term dual antiplatelet therapy (DAPT) was evaluated as a bleeding reduction strategy. However, the strategy of ticagrelor monotherapy has not been exclusively evaluated in patients with acute coronary syndromes (ACS). OBJECTIVE: To determine whether switching to ticagrelor monotherapy after 3 months of DAPT reduces net adverse clinical events compared with ticagrelor-based 12-month DAPT in patients with ACS treated with drug-eluting stents. DESIGN, SETTING, AND PARTICIPANTS: A randomized multicenter trial was conducted in 3056 patients with ACS treated with drug-eluting stents between August 2015 and October 2018 at 38 centers in South Korea. Follow-up was completed in October 2019. INTERVENTIONS: Patients were randomized to receive ticagrelor monotherapy (90 mg twice daily) after 3-month DAPT (n = 1527) or ticagrelor-based 12-month DAPT (n = 1529). MAIN OUTCOMES AND MEASURES: The primary outcome was a 1-year net adverse clinical event, defined as a composite of major bleeding and adverse cardiac and cerebrovascular events (death, myocardial infarction, stent thrombosis, stroke, or target-vessel revascularization). Prespecified secondary outcomes included major bleeding and major adverse cardiac and cerebrovascular events. RESULTS: Among 3056 patients who were randomized (mean age, 61 years; 628 women [20%]; 36% ST-elevation myocardial infarction), 2978 patients (97.4%) completed the trial. The primary outcome occurred in 59 patients (3.9%) receiving ticagrelor monotherapy after 3-month DAPT and in 89 patients (5.9%) receiving ticagrelor-based 12-month DAPT (absolute difference, -1.98% [95% CI, -3.50% to -0.45%]; hazard ratio [HR], 0.66 [95% CI, 0.48 to 0.92]; P = .01). Of 10 prespecified secondary outcomes, 8 showed no significant difference. Major bleeding occurred in 1.7% of patients with ticagrelor monotherapy after 3-month DAPT and in 3.0% of patients with ticagrelor-based 12-month DAPT (HR, 0.56 [95% CI, 0.34 to 0.91]; P = .02). The incidence of major adverse cardiac and cerebrovascular events was not significantly different between the ticagrelor monotherapy after 3-month DAPT group (2.3%) vs the ticagrelor-based 12-month DAPT group (3.4%) (HR, 0.69 [95% CI, 0.45 to 1.06]; P = .09). CONCLUSIONS AND RELEVANCE: Among patients with acute coronary syndromes treated with drug-eluting stents, ticagrelor monotherapy after 3 months of dual antiplatelet therapy, compared with ticagrelor-based 12-month dual antiplatelet therapy, resulted in a modest but statistically significant reduction in a composite outcome of major bleeding and cardiovascular events at 1 year. The study population and lower than expected event rates should be considered in interpreting the trial. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02494895.
引用
- Kim BK, Hong SJ, Cho YH, et al. Effect of Ticagrelor Monotherapy vs Ticagrelor With Aspirin on Major Bleeding and Cardiovascular Events in Patients With Acute Coronary Syndrome: The TICO Randomized Clinical Trial. JAMA. 2020. PMID: 32543684. doi:10.1001/jama.2020.7580
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。